Indeed, we analyzed transcriptomic data from tumors collected prior to ICB treatment across six independent datasets encompassing multiple cancer types treated with anti–PD-1/–PD-L1 or anti–CTLA-4 therapies. Here, CTLA4 is linked to cancer.